Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Settles Junk DNA Patent Suit with Nuvelo and Covance, but not Applera

NEW YORK, Nov. 18 (GenomeWeb News) - Genetic Technologies of Melbourne, Australia, said today that it has settled lawsuits filed against Nuvelo and Covance for infringement of its non-coding DNA patents.

Genetic Technologies initiated legal action against the two companies and Applera in April 2003.

In a statement today, the company said it "will now dismiss the actions against Nuvelo and Covance," and "plans to "focus its efforts on the remaining action against Applera Corporation."

Specific terms of the settlements were not provided.

The company said it also plans to continue "global expansion of the out-licensing of the GTG non-coding patents" - a controversial strategy that has drawn criticism from the scientific community over the past year.

Genetic Technologies has claimed to be in negotiations with 60 potential licensees worldwide. Licensees and cross-licensees for the company's patents include Orchid Biosciences, Pyrosequencing, Nanogen, and Myriad.  

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.